TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02593136

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Home Fortification Product (HFP)
Description: The home fortification product (HFP) is a sachet containing multiple vitamins and nutrients as follows:~Iron (Ferrous Fumarate) 12.5 mg Zinc (Zinc Gluconate) 5 mg Folic Acid 0.160 mg Vitamin-A (Vit-A Acetate) 0.30 mg Vitamin-C (Ascorbic Acid) 30 mg Vitamin-B12 0.9 mcg Iodine 90 mcg Maltodextrin (Base)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant and Young Child Feeding (IYCF) Practices Counseling
Description: Infant and Young Child Feeding (IYCF) Practices Counseling provides direction on breast milk and milk feeding, food variety, and frequency for caregivers of children aged 6 to 18 months. Participants will be visited at least monthly by a field line worker for IYCF counseling and educational materials distribution.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant and Young Child Feeding (IYCF) Practices Counseling
Description: Infant and Young Child Feeding (IYCF) Practices Counseling provides direction on breast milk and milk feeding, food variety, and frequency for caregivers of children aged 6 to 18 months. Participants will be visited at least monthly by a field line worker for IYCF counseling and educational materials distribution.
Study: NCT00912119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epsilon-Aminocaproic Acid
Description: Group B (intermediate dose) will receive a loading dose of EACA of 50 mg/kg over ten minutes followed by a continuous EACA infusion at 20 mg/kg/hr, which will be continued until the end of surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epsilon-Aminocaproic Acid
Description: Group D (extra low dose) will receive a loading dose of EACA of 12.5 mg/kg over ten minutes followed by a continuous EACA infusion at 5 mg/kg/hr, which will be continued until the end of surgery
Study: NCT00496457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Capsules of TRO19622 (125 mg)- Once a day before noon meal during 6 weeks
Study: NCT04623125

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spaced Retrieval Practice
Description: Online picture-naming training with 60 words which the participant experiences word-retrieval difficulties. Cards are shuffled arranged by the computerized training program.
Study: NCT02104388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SJP-0035 Ophthalmic Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of SJP-0035 Ophthalmic Solution
Study: NCT04880902

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sleeve gastrectomy
Description: Laparoscopic sleeve gastrectomy had evident therapeutic effects on preexisting obesity-related comorbidities. All patients were referred for abdominal MSCT with a volumetric assessment of gastric pouch within 1 month of surgery and 1 year postoperatively
Study: NCT01917656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 1.8 mg administered subcutaneously (s.c., under the skin) once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Subjects will continue on their pre-trial metformin tablet treatment, dose unchanged

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Subjects will continue on their pre-trial metformin tablet treatment, dose unchanged

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulphonylurea
Description: Subjects will continue on their pre-trial SU tablet treatment, doses unchanged
Study: NCT03487601

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Active treatment will consist of a mild electrical current (2mA) administered via saline-soaked sponge electrodes placed along the intact scalp for 30 minutes a day for five days.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham transcranial direct current stimulation
Description: Sham stimulation will involve brief delivery of current in a manner that does not result in changes in neuronal firing patterns, but that is perceived as active treatment by participants.
Study: NCT02560506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elastic assisted treadmill walking
Description: Rubber band pulley system that will assist therapists in advancing limbs while gait training. The device is positioned in front of a treadmill and the stretch of the elastic bands when a legs moves backwards on a treadmill is resists the movement and facilitates limb swing when walking.
Study: NCT02909387

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project UPLIFT
Description: UPLIFT is an 8-week distance-delivered mindfulness-based cognitive therapy intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Project UPLIFT
Description: UPLIFT is an 8-week distance-delivered mindfulness-based cognitive therapy intervention.
Study: NCT00928590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost/Timolol Maleate Fixed Combination solution
Study: NCT03029884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Open-Loop DBS
Description: Conventional brain stimulation that is tonically providing stimulation, without feedback

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Stimulation
Description: No Active Stimulation
Study: NCT03715946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection
Description: A fully human anti-programmed death 1 (PD-1) monoclonal antibody

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Description: 45-50 Gy accelerated fractionation in 25 daily fractions, 6 fractions per week
Study: NCT02149888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir/emtricitabine
Description: Once daily Tenofovir/emtricitabine (Truvada®)
Study: NCT01985893

Intervention type: DRUG
Group type: OTHER
Intervention: Lapatinib plus trastuzumab
Description: Comparison of the safety and efficacy of lapatinib plus trastuzumab and lapatinib plus capecitabine.

Intervention type: DRUG
Group type: OTHER
Intervention: Lapatinib plus trastuzumab
Description: Comparison of the safety and efficacy of lapatinib plus trastuzumab and lapatinib plus capecitabine.
Study: NCT04384978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Play Serious Games with a Social Robot (Ryan)
Description: Active Group: Game play and physical activities with Ryan, a socially assistive robot developed at DreamFace Technologies,LLC.
Study: NCT03029884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-Loop DBS
Description: Feedback enabled brain stimulation, where stimulation is provided on demand in response to pain biomarkers.
Study: NCT04641689

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Desk Only
Description: Provision of height-adjustable desk

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Desk Only
Description: Provision of height-adjustable desk

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Program Only
Description: Online modules will promote goal setting, self-monitoring, habit formation, social support, barrier identification, and environmental modifications

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Program Only
Description: Online modules will promote goal setting, self-monitoring, habit formation, social support, barrier identification, and environmental modifications
Study: NCT04662970

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device programming
Description: Non-invasive electrophysiology with 65 ECG leads will be performed in 16 different device programming
Study: NCT02700633

Intervention type: DEVICE
Intervention: Pacemaker
Study: NCT01887054

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tower of Hanoi

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group - non use of Tower of Hanoi
Study: NCT02299518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV and PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV and PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selinexor
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selinexor
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT00886652

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program
Description: Three weekly sessions, with an interval of one day between each, lasting 60 minutes each, and divided into three separate stages: - A 10-minute warm-up (stretching and low intensity aerobic exercises such as slow, gradual walking); - 40 minutes of aerobic exercise on an electric treadmill, with the work intensity maintained at a 60% to 80% of the maximum heart rate; - 10 minutes of winding down and relaxation (stretching exercises, low energy expenditure aerobics and relaxation techniques).
Study: NCT03317301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL151
Description: 2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (1Tab)+Talion Tab (Placebo)(1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (Placebo)(1Tab)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Talion Tab
Description: 2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (Placebo)(1Tab)+Talion Tab (1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (1Tab)
Study: NCT02910505

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enLighten Laser
Description: Laser for tattoo removal
Study: NCT03377140

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hesperidin
Description: 2 capsuls

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: 2 capsuls
Study: NCT01873469

Intervention type: RADIATION
Intervention: Radiochemotherapy
Description: postoperative radiochemotherapy 60 Gy/ Temozolomide
Study: NCT02518464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice per day
Description: Patients will be loaded with 180 mg of Ticagrelor during the enrollment office visit and provided with a 28 day supply of Ticagrelor, 90 mg twice per day. P2Y12 reactivity unit (PRU) testing will be conducted at 7-14 days. If the patient has a positive response, they will have the option of continued access of Ticagrelor 180 mg for another 2 months. Participants will be reminded via text message daily to complete a headache survey on line in order to track their headaches.
Study: NCT01067924

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: Intervention arm will receive 2 motivational interviewing session aimed at increasing maintenance of physical activity upon the completion of a supervised exercise program. Motivational interviews will occur at the end of the structured program and at 3 months post program completion. Outcomes will be collected at 6 months post-program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational interviewing
Description: Intervention arm will receive 2 motivational interviewing session aimed at increasing maintenance of physical activity upon the completion of a supervised exercise program. Motivational interviews will occur at the end of the structured program and at 3 months post program completion. Outcomes will be collected at 6 months post-program.
Study: NCT00265148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: Extended Release Tablets

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo dummy to match
Study: NCT02151773

Intervention type: DRUG
Intervention: Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
Description: Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
Study: NCT00385476

Intervention type: BEHAVIORAL
Intervention: PMKT Questionnaire
Description: Patient Medication Knowledge Tool - Questionnaire entailing the medications the patient is currently taking.
Study: NCT02597062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT01929135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medicated 2% atorvastatin dentifrice
Description: Non surgical periodontal therapy accompanied by medicated 2% atorvastatin dentifrice (20 mg per ml) 2 times a day for two minutes each time, for 30

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non-medicated dentifrice
Description: Non surgical periodontal therapy accompanied by non medicated dentifrice 2 times a day for two minutes each time, for 30 days.
Study: NCT00819793

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CentriMag Ventricular Assist System
Description: All eligible subjects will receive the CentriMag Ventricular Assist System. The system is comprised of a single-use centrifugal blood pump, a motor, a primary drive console, a back up drive console and cannulae. Blood from the failing heart is directed from the ventricle or the atrium to the inlet of the pump via an inlet cannula. Blood exits through the outlet port of the pump through the outlet cannula ultimately to the pulmonary or systemic circulation. The system can be used in either a right, left or biventricular configuration.
Study: NCT02387476

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FRESCA mask first night
Description: FRESCA nasal mask first night

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FRESCA mask first night
Description: FRESCA nasal mask first night
Study: NCT03980314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study: NCT02387476

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP Mask first night
Description: CPAP Nasal Mask first night

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP Mask first night
Description: CPAP Nasal Mask first night
Study: NCT00734747

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medigus SRS endoscopic stapling system
Description: The system is designed to staple the stomach to the esophagus in 2 or 3 locations using a quintuplet of standard B shaped, 4.8 mm titanium staples in each location.
Study: NCT01730248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC424
Description: 5 mg tablets administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC424
Description: 5 mg tablets administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: 10 mg and 50 mg hard gelatin capsules administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: 10 mg and 50 mg hard gelatin capsules administered orally once daily
Study: NCT03419858

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: A well-validated brief mindfulness-based mental training regimen \[four sessions; 20 min/session\] was used to teach patients to independently practice mindfulness meditation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Meditation
Description: A well-validated brief meditation-based mental training regimen \[four sessions; 20 min/session\] was used to teach patients to independently practice closing their eyes and take a deep breath every few minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Slow-Breathing
Description: Study volunteers practiced lowering their breathing rate, across four, 20 minute training sessions, in response to a fluctuating light with the guidance of a trained facilitator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: A 0.15 mg/kg bolus dose of naloxone (Naloxone Hydrichloride, Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, California) in 25ml normal saline was administered over 10 minutes. We also administered a supplementary IV infusion dose of 0.1mg/kg/hour naloxone immediately after bolus infusion ceased till the end of the experiment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone
Description: A 0.15 mg/kg bolus dose of naloxone (Naloxone Hydrichloride, Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, California) in 25ml normal saline was administered over 10 minutes. We also administered a supplementary IV infusion dose of 0.1mg/kg/hour naloxone immediately after bolus infusion ceased till the end of the experiment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone
Description: A 0.15 mg/kg bolus dose of naloxone (Naloxone Hydrichloride, Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, California) in 25ml normal saline was administered over 10 minutes. We also administered a supplementary IV infusion dose of 0.1mg/kg/hour naloxone immediately after bolus infusion ceased till the end of the experiment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: A 0.15 mg/kg bolus dose of saline in 25ml normal saline was administered over 10 minutes. We also administered a supplementary IV infusion dose of 0.1mg/kg/hour saline immediately after bolus infusion ceased till the end of the experiment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: A 0.15 mg/kg bolus dose of saline in 25ml normal saline was administered over 10 minutes. We also administered a supplementary IV infusion dose of 0.1mg/kg/hour saline immediately after bolus infusion ceased till the end of the experiment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: A 0.15 mg/kg bolus dose of saline in 25ml normal saline was administered over 10 minutes. We also administered a supplementary IV infusion dose of 0.1mg/kg/hour saline immediately after bolus infusion ceased till the end of the experiment.
Study: NCT04384978

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Play Solitary Games Without a Social Robot
Description: Control Group: Group 2 will play solitary games (e.g., word puzzles) and activities but will have no interaction with Ryan.
Study: NCT01691508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Mepolizumab is a fully humanised Immunoglobulin G antibody (IgG1, kappa) with human heavy and light chain frameworks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Will be available as an equivalent volume of 0.9% sodium chloride.
Study: NCT03135405

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated messages
Description: Automated motivational messages and visit and medication reminders will be provided via interactive voice response calls or text messages.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home BP monitors
Description: Participants will have the option of receiving home blood pressure monitors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care partner reminders
Description: Participants will have the option of designating a care partner who will also receive automated reminder calls or text messages.
Study: NCT01691508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCS (prednisone/prednisolone)
Description: Oral Corticosteroid (prednisone/prednisolone)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCS (prednisone/prednisolone)
Description: Oral Corticosteroid (prednisone/prednisolone)
Study: NCT01917838

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MFG plus MyMFG
Description: Specific aim is to utilize mHealth to improve the Design and Do process of HW within the context of the Family Groups for Youth with Behavioral Difficulties (MFG) intervention, an EBT for DBDs in youth and their families who seek assistance at outpatient mental health clinics in urban communities.~The first component focuses on delivering HW via a highly engaging, multiplayer, interactive, cooperative, and skill-building game platform aimed at improving the Design and Do process of HW. The second component focuses on targeting factors putatively related to poor HW implementation within the Do process.
Study: NCT05493930

Intervention type: OTHER
Intervention: The hospital where the treatment is performed

Intervention type: OTHER
Intervention: The hospital where the treatment is performed

Intervention type: OTHER
Intervention: The hospital where the treatment is performed
Study: NCT02226952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILN 2061 W, low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILN 2061 W, medium dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILN 2061 W, medium dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILN 2061 W, high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILN 2061 W, high dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03027115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Tamsulosin treatment for 7 days pre-operatively
Study: NCT02405325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: intervention activities will remain at the daily level, including using pedometers, having daily goals, attendance at Peer lead group walks and recognition of efforts through monthly celebrations and bi-weekly goal tracking with peer Health Coaches.
Study: NCT02108925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: supplementary oxygen during exercise
Study: NCT00004160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study: NCT04681703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led program on accuracy of blood pressure self-measurement
Description: The training program was performed in accordance with current guidelines and consisted of a 1-h educational session led by one family nurse (FN) tasked with instruction of the patients. During the training program the FN emphasized that since morning and evening blood pressure (BP) values can widely differ, especially in patients taking medications, BP should be measured twice a day, in the morning and at evening, at specific fixed times (between 6:00 am and 9:00 am and between 6:00 pm and 9:00 pm) at least during the first week of monitoring. Thereafter, measurements can be taken before antihypertensive drugs are taken.
Study: NCT01683032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPH
Description: a capsule containing 20 mg